[an error occurred while processing this directive] | [an error occurred while processing this directive]
Radiation dose and fractionation regimen for limited stage small cell lung cancer: a survey of current practice patterns of Chinese radiation oncologists
Xu Chang1, Li Meng2, Chen Ming3, Zhu Shuchai4, Bi Nan5, Cai Xuwei6, Yuan Shuanghu7, Cao Jianzhong8, Hu Xiao9, Li Jiancheng10, Zhou Wei11, Wang Ping1, Wang Jun2, Zhao Lujun1, Liu Ningbo1
1Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China; 2Department of Radiation Oncology, Konggang Branch of Tianjin Cancer Hospital, Tianjin 300308, China; 3Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510055, China; 4Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 5Department of Radiation Oncology, National Cancer Center / National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 6Department of Radiation Oncology, Shanghai Chest Hospital, Shang Hai 200030, China; 7Department of Radiation Oncology, Shandong Cancer Hospital, Ji'nan 250117, China; 8Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China; 9Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310005, China; 10Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou 350014, China; 11Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China
AbstractObjective To investigate the radiation dose and fractionation regimens for limited stage small cell lung cancer (LS-SCLC) in Chinese radiation oncologists. Methods Over 500 radiation oncologists were surveyed through questionnaire for radiation dose and fractionation regimens for LS-SCLC and 216 valid samples were collected for further analysis. All data were collected by online questionnaire designed by WJX software. Data collection and statistical analysis were performed by SPSS 25.0 statistical software. The differences in categorical variables among different groups were analyzed by Chi-square test and Fisher's exact test. Results Among 216 participants, 94.9% preferred early concurrent chemoradiotherapy, 69.4% recommended conventional fractionation, 70.8% preferred a total dose of 60 Gy when delivering conventional radiotherapy and 78.7% recommended 45 Gy when administering hyperfractionated radiotherapy. Conclusions Despite differences in LS-SCLC treatment plans, most of Chinese radiation oncologists prefer to choose 60 Gy conventional fractionated radiotherapy as the main treatment strategy for LS-SCLC patients. Chinese Society of Clinical Oncology (CSCO), National Comprehensive Cancer Network (NCCN) and Chinese Medical Association guidelines or expert consensus play a critical role in guiding treatment decision-making.
Corresponding Authors:
Liu Ningbo, Email: liuningbo@tjmuch.com; Zhao Lujun, Email: zhaolujun@tjmuch.com
Cite this article:
Xu Chang,Li Meng,Chen Ming et al. Radiation dose and fractionation regimen for limited stage small cell lung cancer: a survey of current practice patterns of Chinese radiation oncologists[J]. Chinese Journal of Radiation Oncology, 2023, 32(2): 93-98.
Xu Chang,Li Meng,Chen Ming et al. Radiation dose and fractionation regimen for limited stage small cell lung cancer: a survey of current practice patterns of Chinese radiation oncologists[J]. Chinese Journal of Radiation Oncology, 2023, 32(2): 93-98.
[1] van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer[J]. Lancet, 2011,378(9804):1741-1755. DOI: 10.1016/S0140-6736(11)60165-7. [2] Wang P, Zou J, Wu J, et al.Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of east China during 2011-2015[J]. J Thorac Dis, 2017,9(7):1973-1979. DOI: 10.21037/jtd.2017.06.102. [3] Warde P, Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? a meta-analysis[J]. J Clin Oncol, 1992,10(6):890-895. DOI: 10.1200/JCO.1992.10.6.890. [4] Sabari JK, Lok BH, Laird JH, et al.Unravelling the biology of SCLC: implications for therapy[J]. Nat Rev Clin Oncol, 2017,14(9):549-561. DOI: 10.1038/nrclinonc.2017.71. [5] Kalemkerian GP.Small Cell Lung Cancer[J]. Semin Respir Crit Care Med, 2016,37(5):783-796. DOI: 10.1055/s-0036-1592116. [6] Kalemkerian GP, Loo BW, Akerley W, et al.NCCN guidelines insights: small cell lung cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018,16(10):1171-1182. DOI: 10.6004/jnccn.2018.0079. [7] Farrell MJ, Yahya JB, Degnin C, et al.Timing of thoracic radiation therapy with chemotherapy in limited-stage small-cell lung cancer: survey of US radiation oncologists on current practice patterns[J]. Clin Lung Cancer, 2018,19(6):e815-e821. DOI: 10.1016/j.cllc.2018.04.007. [8] Kubota K, Hida T, Ishikura S, et al.Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study[J]. Lancet Oncol, 2014,15(1):106-113. DOI: 10.1016/S1470-2045(13)70511-4. [9] Farrell MJ, Yahya JB, Degnin C, et al.Radiation dose and fractionation for limited-stage small-cell lung cancer: survey of US radiation oncologists on practice patterns[J]. Clin Lung Cancer, 2019,20(1):13-19. DOI: 10.1016/j.cllc.2018.08.015. [10] Komaki R, Khalid N, Langer CJ, et al.Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey[J]. Int J Radiat Oncol Biol Phys, 2013,85(4):1082-1089. DOI: 10.1016/j.ijrobp.2012.10.016. [11] Faivre-Finn C, Snee M, Ashcroft L, et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017,18(8):1116-1125. DOI: 10.1016/S1470-2045(17)30318-2. [12] Proudhom MA, Noël G, Mazeron JJ.[Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. Phase III comparison of twice-daily split course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma][J]. Cancer Radiother, 2000,4(4):319-320. [13] Zayed S, Chen H, Ali E, et al.Is There a Role for hypofractionated thoracic radiation therapy in limited-stage small cell lung cancer? a propensity score matched analysis[J]. Int J Radiat Oncol Biol Phys, 2020,108(3):575-586. DOI: 10.1016/j.ijrobp.2020. 06.008. [14] Almahmudi M, Atwal P, Casey S, et al. Pattern of practice and comparison of thoracic radiotherapy for the radical treatment of limited-stage small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020,108(3):e117-e118. DOI: 10.1016/j.ijrobp.2020.07.1248. [15] Bogart JA, Wang XF, Masters GA, et al.Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538[J]. J Clin Oncol,2021,39(15_suppl):8505. DOI:10.1200/JCO.2021.39.15_suppl.8505. [16] Gronberg BH, Killingberg KT, Fløtten Ø, et al.Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC)[J]. J Clin Oncol, 2020,38(15_suppl):9007.
2023, Vol. 32 
